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Abstract: Dimethylarginine dimethylaminohydrolase (DDAH) is a highly conserved hydrolytic
enzyme found in numerous species, including bacteria, rodents, and humans. In humans, the
DDAH-1 isoform is known to metabolize endogenous asymmetric dimethylarginine (ADMA) and
monomethyl arginine (L-NMMA), with ADMA proposed to be a putative marker of cardiovascular
disease. Current literature reports identify the DDAH family of enzymes as a potential therapeutic
target in the regulation of nitric oxide (NO) production, mediated via its biochemical interaction with
the nitric oxide synthase (NOS) family of enzymes. Increased DDAH expression and NO production
have been linked to multiple pathological conditions, specifically, cancer, neurodegenerative disorders,
and septic shock. As such, the discovery, chemical synthesis, and development of DDAH inhibitors
as potential drug candidates represent a growing field of interest. This review article summarizes
the current knowledge on DDAH inhibition and the derived pharmacokinetic parameters of the
main DDAH inhibitors reported in the literature. Furthermore, current methods of development and
chemical synthetic pathways are discussed.
Keywords: dimethylarginine dimethylaminohydrolase; arginine; nitric oxide; asymmetric
dimethylarginine; monomethyl arginine; enzyme inhibitors; organic synthesis
1. Introduction
Dimethylarginine dimethylaminohydrolase (DDAH) is a modulator of the nitric oxide (NO)
pathway and is responsible for the metabolism of methylated arginines [1]. DDAH is conserved
throughout many species and has been demonstrated to pre-date evolution of the Nitric Oxide
Synthase (NOS) family [2], suggesting an alternative function for methylated arginines independent to
their role as NOS regulatory molecules. Two different isoforms of human DDAH have been identified,
with DDAH-1 and DDAH-2 sharing 62% homology. DDAH-1 is primarily expressed in different areas
of the brain [3], the dorsal root ganglia and the spinal dorsal horn [4]. DDAH-2 appears prevalent in
pancreatic islet cells [5] and infected tissues [6]. In addition, Altman et al. reported a study showing
high expression of DDAH-2 in porcine immune tissues [7]. The two isoforms are both expressed in
kidney [8–10], heart [11,12], adipose tissue [13], placenta and trophoblasts [14], and the liver [15–18].
Phylogenetic analyses indicate DDAH-1 was generated by duplication of the genomic segment located
on chromosome 6 comprising DDAH-2 [2,19]. Although hydrolysis of asymmetrically methylated
arginines appears to be the primary function of DDAH-1, alternate roles for both DDAH isoforms
are evident when they independently interact with other enzymes [20,21]. For example, DDAH-1 is
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reported to bind the tumour suppressor protein neurofibromin, resulting in increased phosphorylation
of neurofibromin by protein kinase A (PKA) [20] and is additionally reported to regulate the levels of
phosphorylated protein kinase B (p-Akt) by increasing Ras activity via a mechanism independent to
the NOS pathway [22]. Similarly, DDAH-2 is known to interact with PKA causing the induction of
vascular endothelial growth factor (VEGF) via phosphorylation of the Sp1 transcription factor [21].
Asymmetric dimethylarginine (ADMA, 1), monomethylarginine (L-NMMA, 2), and symmetric
dimethylarginine (SDMA, 3) are endogenous methylated arginines (Figure 1). They are formed by
two biochemical processes: (1) the initial post-translational methylation of protein arginine residues
which is catalyzed by the protein arginine methyltransferases (PRMT’s); and (2) the subsequent
release from their respective methylated protein(s) by proteolysis [23]. Once released into the
cytosol, transport and efflux of the methylated arginines is mediated by the y+ cationic amino
acid (CAT-1) transporter [24]. ADMA and L-NMMA inhibit all members of the NOS family of
enzymes [25–30], while SDMA competes with L-arginine, a NOS substrate, for transport by the y+
cation transporter [31]. Different enzymes play a role in the metabolism of methylated arginines,
particularly alanine-glyoxylate aminotransferase 2 (AGXT2) [32–34]. However, ADMA and L-NMMA,
but not SDMA, are primarily converted by DDAH-1 to L-citrulline (4) and dimethylamine (5) or
monomethylamine (6), respectively [35] (Scheme 1).
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In contrast, reduced ADMA concentrations have been demonstrated in other disease states, such as 
amyotrophic lateral sclerosis [51], multiple sclerosis [43], Alzheimer’s disease and dementia [52,53]. 
ADMA has also been shown to have neuroprotective effects in a model of Parkinson’s disease [54]. 
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Scheme 1. ADMA and L-NMMA are substrates for DDAH-1 and are converted to L-citrulline (4) and
an amine species 5 or 6.
The role of ADMA accumulation and impaired DDAH expression and/or activity in the
pathophysiology of several diseases is well documented [36–44]. Increased plasma or serum
ADMA concentrations have been associated with coronary events [45–47], renal disease [29,37],
atherosclerosis [48], and cerebrovascular disease [49,50]. Up-regulation of DDAH expression and
activity might, therefore, represent a good strategy in the treatment of the aforementioned pathologies
to increase ADMA metabolism and lower its plasma concentrations.
In contrast, reduced ADMA concentrations have been demonstrated in other disease states, such
as amyotrophic lateral sclerosis [51], multiple sclerosis [43], Alzheimer’s disease and dementia [52,53].
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ADMA has also been shown to have neuroprotective effects in a model of Parkinson’s disease [54].
Furthermore, DDAH overexpression in tumours enhances their metastatic potential [42,55,56]. Several
reports also show that inhibition of NO synthesis results in significant anti-angiogenic effects both
in vitro and in vivo, with potential beneficial effects in cancer [57–61]. Moreover, excessive NO
concentrations play a key role in the pathophysiology of septic shock [62–65] (an early therapeutic
approach for the treatment of septic shock involved the administration of 546C88 (L-NMMA) to inhibit
NOS and reduce NO synthesis, however the increase in mortality in patients receiving L-NMMA caused
the termination of the clinical trial in phase III [66]. Further analysis of the data revealed that mortality
was associated with elevated L-NMMA concentrations; conversely, lower L-NMMA concentrations
were associated with improved survival [36]. In this context a more controlled, indirect modulation of
methylated arginine concentrations through pharmacological DDAH-1 inhibition (DDAH-2 knockout
affects outcome in models of polymicrobial sepsis [44]) might represent an alternative strategy, and
appears particularly promising in a rat model of septic shock [67]). In these circumstances, DDAH
inhibition could exert a controlled inhibition of the NO synthesis by increasing ADMA concentrations
and offering a new approach in the treatment of these diseases.
Therefore, alterations in DDAH and NOS activity might exert either beneficial or toxic effects,
according to specific experimental models and disease conditions. The potential of DDAH as a
molecular target in the treatment of these pathological conditions has led several groups to study
the endogenous mechanisms involved in the modulation of the expression and activity of human
DDAH-1 and DDAH-2 [68]. The elucidation of these mechanisms may identify new strategies for the
pharmacological activation or inhibition of these enzymes to restore physiological homeostasis after
pathological imbalance. Since the discovery of the DDAH family of enzymes in 1987 [35], a number of
research groups have identified inhibitors with the aim of developing such therapeutics. While no
‘selective’ DDAH inhibitor has entered clinical trials, numerous compounds have been synthesized
that act as prototypic in vitro inhibitors. Herein, we discuss all published DDAH inhibitors according
to their chemical structure (‘substrate-like’ and ‘non-substrate-like’), and summarize the details of
their synthetic pathways as well as how they alter the pharmacokinetic parameters for L-citrulline
formation by DDAH.
2. Endogenous Modulation of DDAH Activity
The production of specific gene products, both in terms of RNA and proteins, is physiologically
regulated by a plethora of mechanisms and can be triggered or silenced by various stimuli and factors.
Of particular note, DDAH activity is reported to be inhibited by divalent transition metals [69,70]
and it is known that elevated zinc(II) concentrations are associated with oxidative stress in numerous
pathological conditions [71–73].
S-Nitrosylation of the enzyme’s cysteine residues is a further important post-translational
regulatory mechanism [74] and is generally associated with increased expression of inducible NOS
(iNOS). The induction of iNOS generates excessive NO that can bind covalently (but reversibly) to the
thiol (SH) moiety of each DDAH cysteine [74]. The apparent S-nitrosylation of the catalytic DDAH
cysteine residue results in DDAH inhibition. This in turn causes the subsequent accumulation of
DDAH substrates, ADMA and L-NMMA, which eventually reach concentrations that reversibly inhibit
the NOS enzymes [75].
Oxidative stress additionally modulates DDAH activity. Factors associated with oxidative stress,
including shear stress [76], tumour necrosis factor α (TNF-α), oxidized low density lipoprotein
(LDL) [76], and homocysteine [77] each suppresses DDAH expression and activity. In contrast,
antioxidant mediators such as probucol [78], estradiol [79], and interleukin-1β (IL-1β) [80] up-regulate
DDAH expression. Moreover, nicotine and cigarette smoking have been shown to decrease DDAH
expression and activity in endothelial cells, with consequential accumulation of ADMA, NOS
inhibition, and endothelial damage [81,82]. Furthermore, it is known that selective down-regulation of
DDAH-1 and up-regulation of DDAH-2 occurs when angiotensin II binds to the type 1 angiotensin
receptor (AT1-R), linking DDAH transcription to angiotensin-induced inflammation [8]. In addition,
epigenetic modifications are known to alter DDAH-2 regulation at the promoter. For example, DNA
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hypermethylation has the ability to suppress DDAH-2 transcription, while histone acetylation has the
ability to up-regulate DDAH-2 transcription [83].
3. Pharmacological Induction of DDAH
As a result of diminished DDAH activity and/or accumulation of ADMA and L-NMMA in various
disease states, several studies have investigated the effects of restoring or increasing DDAH expression.
Statin treatment is associated with a significant reduction in ADMA concentrations [84–86], and an
increase in both DDAH-1 and DDAH-2 expression and activity [87–89]. Another class of compounds
enhancing ADMA metabolism via DDAH up-regulation is represented by the farnesoid X receptor
(FXR) agonists. GW4064 upregulates both DDAH-1 and the cationic transporter CAT-1, leading to
increased ADMA cellular uptake and metabolism, and decreased serum ADMA concentrations [15,90].
Another FXR agonist, INT-747, can increase DDAH-1 expression [91,92], however this is not associated
with significant changes in ADMA and NO concentrations [91]. The lipid lowering drug probucol
also lowers ADMA concentrations [93] via up-regulation of both DDAH expression and activity, and
down-regulation of PRMT-1 expression [78,94]. Another lipid lowering drug, fenofibrate, decreases
ADMA concentrations by restoring DDAH activity in conditions of oxidative stress [95]. Additionally,
the oral antidiabetic drug pioglitazone and the β1 receptor blocker nebivolol both decrease serum
ADMA concentrations by increasing DDAH-2 expression [96–99].
4. Pharmacological Inhibition of DDAH
Contrary to the comments in Section 3 above, there is a growing body of evidence to suggest that
the modulation of DDAH enzyme activity may be utilized in conditions characterized by excessive
NO production [36,67]. The remainder of this review will focus on highlighting the current knowledge
associated with the main DDAH inhibitors reported in the literature to date.
4.1. Substrate-Like Inhibitors
4.1.1. S-Nitroso-L-Homocysteine (HcyNO)
Since the identification of S-nitrosylation as an important mechanism of DDAH regulation,
the discovery of L-homocysteine’s ability to inhibit DDAH-1 led to the development of
S-nitroso-L-homocysteine (HcyNO, 9), an endogenous S-nitrosothiol and a source of endogenous
NO [100–102]. Synthesis and characterisation of HcyNO as a bovine DDAH inhibitor was reported
by Knipp et al. (2005) [102]. HcyNO was synthesized in near quantitative yield in a two-step reaction
(Scheme 2) via alkaline hydrolysis of commercially available L-homocysteine thiolactone hydrochloride
(7) to L-homocysteine (8) [103], followed by S-nitrosylation of L-homocysteine with sodium nitrite
(NaNO2) and acidification to afford HcyNO (9) [104]. Alternatively, S-nitrosylation can be undertaken
directly on commercially available L-homocysteine (8). Mild reaction conditions are required, and
excellent yields make HcyNO simple to prepare on a large scale.
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Scheme 2. Synthetic scheme for generating HcyNO (9). Reagents and Conditions: (i) 5 M NaOH, 37 ˝C,
5 min, 96%; (ii) NaNO2, 2 M HCl, 37 ˝C, 15 min, >99%.
HcyNO irreversibly inhibits DDAH by covalently binding o the putative catalytic cysteine with
an inhibitory constant (Ki) f 690 µM [105]. Mass spectrometry analyses using diff ent isotopic
forms of S-nitroso-L-homocysteine (Hcy15NO and HcyN18O) and oxygen-18 labelled water (H218O)
demonstrated that HcyNO forms a N-thiosulfoximide adduct with cysteine 273 (Cys273) of bovine
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DDAH-1. The authors’ proposed mechanism of inhibition requires the lone pair of electrons of the
Cys273 SH to attack the S-nitroso group in HcyNO to eliminate a hydroxyl anion (Scheme 3). This
mechanism is likely stabilized by neighbouring amino acids, namely His172. A further hydroxyl anion
originating from water attacks the cationic sulfur of the conjugated intermediate, and subsequently
rearranges to give the covalent thiosulfoximide adduct [102].
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4.1.2. 2-Chloroacetamidine and N-But-3-ynyl-2-chloroacetamidine
Stone et al. [106] identified 2-chloroacetamidine (11) as a nonspecific inhibitor of two enzymes
of the amidinotransferases superfamily, Pseudomonas aeruginosa DDAH (PaDDAH) and human
peptydilarginine deaminase (PAD). 2-Chloroacetamidine (11, Scheme 4) is a commercially available
compound bearing a 2-chloromethylene chain and an amidinium group, which partially resembles
arginine. It can be synthesized via reaction of chloroacetonitrile (10) with sodium methoxide followed
by treatment with ammonium chloride [107,108]. 2-Chloroacetamidine acts as a weak irreversible
amidinotransferase inhibitor with greater affinity for PaDDAH, relative to PAD4 (Table 1). Data
acquired by electrospray ionization mass spectrometry revealed the formation of an irreversible
thiouronium-enzyme adduct whereby the loss of chlorine from the inhibitor is observed [106].
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Scheme 4. Synthetic scheme for generating 2-chloroacetamidine (11) (the conditions described afford
the hydrochloride salt). Reagents and Conditions: (i) NaOMe, dry MeOH, overnight; (ii) AcOH, NH4Cl,
reflux, 6 h, 89%.
Table 1. Reported inhibitory constants for 2-chloroacetamidine (11) [106].
Enzyme Ki (mM) Kinact (min´1)
PaDDAH 3.1 ˘ 0.8 1.2 ˘ 0.1
PAD4 20 ˘ 5 0.7 ˘ 0.1
The addition of an N-but-3-ynyl substit ent to e ac tamidine group of 2-ch oroacet midine led
to formation of the human DDAH-1 probe, N-but-3-ynyl-2-chloro-acetamidine (18, Scheme 5) [109].
N-But-3-ynyl-2-chloro-acetamidine binds within the putative active-site, while the N-alkynyl
substituent is reacted with biotin-PEO3-azide under copper catalysis via click chemistry. Successful
conjugation can be easily detected in immunoblots using an anti-biotin antibody [109]. Synthesis of the
N-but-3-ynyl-2-chloro-acetamidine probe was achieved in five steps using two modules (Scheme 5).
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Amine module 15 was prepared in three steps: activation of the terminal hydroxyl group of 3-butyn-1-ol
(12) through mesylation to afford 13 in 62% yield, followed by conversion to amine 15 via azide
intermediate 14 in 49% yield across two steps. The imidic ester module 17 was obtained in moderate
yields (approximately 48%) by reacting chloroacetonitrile (10) with anhydrous ethanol (16) in the
presence of dry hydrochloric acid gas. Final coupling between amine 15 and the imidic ester 17
proceeds under basic aqueous conditions to afford probe N-but-3-ynyl-2-chloro-acetamidine (18) in
reasonable yields (approximately 63%). To date, no data are available regarding the selectivity of
N-but-3-ynyl-2-chloro-acetamidine for human DDAH-1 and the potential cross reactivity of this probe
with PaDDAH.
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Scheme 5. Synthetic scheme for generating the DDAH-1 biochemical probe N-but-3-ynyl-2-chloro-
acetamidine (18). Reagents and Conditions: (i) DCM, TEA, DMAP, MsCl, 0 ˝C for 2 h then 25 ˝C for 3 h,
62%; (ii) anhydrous DMF, NaN3, 70 ˝C, 3.5 h; (iii) Et2O, Ph3P, 0 ˝C for 2 h, addition of H2O, then 25 ˝C
for 20 h, 49% (two steps); (iv) dry HCl(g) at 0 ˝C for 1 h, stop HCl(g), then 0 ˝C for 4 h and RT overnight
48%–76%; (v) H2O, pH = 10, 0 ˝C for 3 h, 25 ˝C for 2 h, neutralized, RT for 1.5 days, 62%. Adapted
with permission from [109]. Copyright 2009 American Chemical Society.
4.1.3. (S)-2-Amino-4-(3-Methylguanidino)butanoic Acid Analogues
Screening experiments with a library comprising 26 analogues of ADMA (1) and L-NMMA
(2) identified (S)-2-amino-4-(3-methylguanidino)butanoic acid (4124W, 21), as a mammalian DDAH
inhibitor [110]. The original synthesis of 4124W (21), first described by Ueda et al. in 2003 [80] is shown
in Scheme 6, and was achieved by coupling N,S-dimethylthiopseudouronium iodide (19) with the
copper complex of 2,4-diamino-n-butyric acid dihydrochloride (20) [32,111]. 4124W (21) was finally
crystallized as the hydrochloride salt.
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Scheme 6. Synthetic scheme for generating (S)-2-amino-4-(3-methylguanidino)butanoic acid (4124W),
as reported by Ueda et al. [80] using the methods of Ogawa et al. [32] and Corbin et al. [111]. Reagents and
Conditions: (i) (1) 2,4-diamino-n-butyric acid dihydrochloride (20), copper acetate, 1:1 NH4OH/H2O;
(2) N,S-dimethylthiopseudouronium iodide (19) RT, 24 h; (3) Dowex 50WX4 (NH4+ form), 4124W (21)
was crystallized as the hydrochloride salt.
High chemical and structural similarity between 4124W and the DDAH substrate L-NMMA exists
(compound 21, Scheme 6, and compound 2, Figure 1), and although exhibiting weak DDAH inhibition
(IC50 = 416 µM) [110], this prompted Rossiter et al. [112] to synthesize a further 34 compounds based
on the 4124W structure. Furthermore, Rossiter et al. [112] reported an alternative synthetic approach,
which although requiring three steps, is synthetically versatile and was applied to develop their
library of 4124W analogues. Rossiter’s strategy utilized protected intermediates to avoid complications
associated with the purification of polar amino acids. Intermediate 24 (Scheme 7) is generated from
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commercially available N,N1-bis-tert-butoxycarbonylpyrazole-1H-carbox-amidine (22) by Mitsunobu
reaction with alcohol 23 containing the desired R1 group, followed by reaction with (S)-tert-butyl
4-amino-2-((tert-butoxycarbonyl)amino)butanoate (25) to afford the protected amino acid analogue 26
(Scheme 7). Cleavage of the Boc protecting groups is achieved with a 4 M solution of HCl in 1,4-dioxane
and produced 4124W (21) in moderate yields (approximately 44%) or analogues 27 in moderate to
good yields (12%–67%).
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Additionally, Rossiter et al. developed a synthetic method for N,N-disubstituted
alkylguanidinobutanoic acids and N-arylguanidines (Scheme 8). This involved reacting N,N’-bis-
tert-butoxycarbonylpyrazole-1H-carboxamidine (22) with Boc-homoserine-tert-butyl ester (30),
whereby the pyrazole group in the intermediate 31 is displaced by the reaction with amine 32 containing
the desired R1 and R2 groups.
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Deprotection of the amino acid analogues 33 is carried out using the same acidic conditions
described in the synthesis of Rossiter’s 4124W analogues in Scheme 7 and provides analogues 34
in low to moderate yields (0.29%–41%). Each analogue’s inhibitory potential was assessed based
on the reduced conversion of [14C]-NMMA to [14C]-citrulline by rat DDAH. Screening experiments
revealed N-monosubstitution to be more effective than disubstitution, and that a R1 substituent
comprising a N-2-methoxyethyl group increased inhibitor binding affinity (viz. compound 27a;
IC50 = 189 µM; Scheme 7). Furthermore, a series of N-2-methoxyethyl guanidinobutanoate esters [112]
was synthesized via thionyl chloride promoted esterification with alcohol containing the desired R3
group (Scheme 7). The generated benzyl ester 29a resulted in substantial improvement in DDAH-1
inhibition (IC50 = 27 µM). A series of amide analogues based on structures 29 (structures omitted)
exhibited poor DDAH-1 inhibitory potentials.
4.1.4. NG-Substituted-L-Arginine Analogues
Rossiter et al. [112] also synthesized a library of N-substituted arginine analogues. A significant
increase in inhibitor binding affinity was obtained for NG-(2-methoxyethyl)-L-arginine (commonly
known as L-257 (compound 39; IC50 = 22 µM; Scheme 9) and its corresponding methyl ester (also
known as L-291 (compound 40; IC50 = 20 µM; Scheme 9), relative to compound 27a (Scheme 7) that
contains one less carbon within the main-chain. Interestingly, the benzyl ester of L-257 did not increase
DDAH-1 inhibition as was observed with compound 29a. These data suggest that arginine analogues
may bind differently within the putative DDAH-1 active-site. Moreover, neither the corresponding
methyl amide of L-257, nor the (R)-isomer of L-257 (structures omitted) resulted in DDAH-1 inhibition.
The synthesis of L-257 (39) is represented in Scheme 9. The reaction sequence follows a
similar approach to that described in the synthesis of the (S)-2-amino-4-(3-methylguanidino)butanoic
acid analogues, using Boc protected amino acid analogues. Firstly, 2-methoxyethyl pyrazole
carboxamidine (36) is prepared under Mitsunobu conditions [113] from 2-methoxyethanol (35) and
N,N1-bis-tert-butoxycarbonylpyrazole-1H-carboxamidine (22). This intermediate 36 is reacted with
Boc-Orn-OBut (37) to introduce the N-alkyl-guanidino group to compound 38. Final deprotection of
38 with 4 M HCl in 1,4-dioxane afforded L-257 (39) in 44% overall yield. L-257 can be subsequently
esterified to afford L-291 (40) in yields of approximately 80%.
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Scheme 9. Synthetic scheme for generating L-257 (39) and L-291 (40). Reagents and Conditions: (i) DEAD,
Ph3P, THF, 0 ˝C-RT, 3–16 h; (ii) DIPEA, CH3CN, RT, 24 h; (iii) 4 M HCl/1,4-dioxane, 24–72 h, 44%
overall; (iv) SOCl2, 0 ˝C for 30 min, reflux for 1 h, RT overnight, 80%. Adapted with permission
from [112]. Copyright 2005 American Chemical Society.
Both L-257 (39) a d L-291 (40) inhibit DDAH-1 in vivo [112]. They are non-cytotoxic and selective
for DDAH-1 against the three main isoforms of NOS [112,114] and arginase [115], an enzyme responsible
for the metabolism of L-arginine into urea and ornithine [112,114,115]. L-257 (39) was utilized by
Kotthaus et al. [114] as a validated active ‘parent’ compound for determining viable lead compounds,
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and to obtain initial structure-activity relationships (SARs) for those leads. In particular, the role of
the N-substituent in DDAH inhibition was investigated as the guanidino moiety is considered to
be important in the proposed catalytic mechanism and binding to the enzyme [116]. In the work
undertaken by Kotthaus et al., the NG-(2-methoxyethyl) side-chain was varied along with the degree of
guanidine substitution. Similarly, Tommasi et al. synthesized further L-257 derivatives with differing
side-chains [117]. In both studies, the NG-(2-methoxyethyl) side-chain conferred inhibitors with activity
toward DDAH-1. N-monosubstituted examples are represented in Table 2.
Table 2. Inhibitory parameters for the N-monosubstituted L-arginine analogues with varied
N-substituents (R groups) [114,117].
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of five carboxylate bioisosteres of L-257 (compounds 44a–c; Scheme 10, 49a–b; Scheme 11).
In com un s 44a–c (Scheme 10), the carboxylic acid moiety is modified by introducing an acyl
methyl sulfonamide 44a (2-amino-5-(3-(2- ethoxyethyl)gua i ino)-N-(methylsulfonyl)-pentanamide;
ZST316), an O-meth l-hydroxamate 44b and a hydroxamate 4 c. The replacement is introduced
on Z-or ithine(Boc)-OH (41) in moderate to good yields (51%–86%) to afford 42, followed by the
quantit tive cleavage of Boc protected 42 with 4 M HCl in 1,4-di xane. Guanidination of 42 with
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Bioisosteric replaceme t of the carboxylic acid moiety in L-257 with O-methyl hydroxamate 44b
and hydroxam te 44c resulted in a decrease in DDAH-1 inhibition (IC50 = 230 and 131 µM, respectively).
By contrast, introduction of an acyl methyl sulfonamidic moiety in ZST316 (44a) led to signific nt
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Compound ZST316 (44a) is the most potent human DDAH-1 i hibitor with ‘substrate-like’ structure
reported in the literature to date.
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Scheme 11) [117]. The synthesis of these inhibitors with azole bioisosteric groups is achieved via 
conversion of the terminal carboxylic acid in 41 to primary amide 45 in quantitative yields using 
isobutylchloroformate, N-methylmorpholine, and aqueous ammonia. Primary amide 45 is then 
converted to nitrile 46 using trifluoroacetic anhydride and triethylamine in 47% yield. Compound 46 
is guanylated [112] (see Sections 4.1.3 and 4.1.4, Schemes 7 and 9) to afford compound 47, from 
which the heterocycle is constructed from the nitrile. The tetrazole is introduced by treating nitrile 47 
with sodium azide in the presence of zinc(II) bromide to afford compound 48a, using the click 
chemistry procedure reported by Demko and Sharpless [120]. Although the use of zinc(II) bromide 
in the synthesis of Boc-amino tetrazoles derived from α-amino acids has been reported [121], the use 
of a Lewis acid may result in partial deprotection of compound 48a during the reaction. Ammonium 
chloride represents an alternative reagent [122]. The 5-oxo-1,2,4-oxadiazole 48b is synthesized from 
nitrile 47 using hydroxylamine hydrochloride and sodium bicarbonate in DMSO, followed by 
treatment with CDI and DBU [123]. Acidic deprotection of 48a–b is achieved as described previously 
[117,119]. Despite obtaining lower yields for heterocyclic adducts 49a–b (7%–13%) relative to 
bioisosteres 44a–c (19%–32%), the inhibitory potential of 5-oxo-1,2,4-oxadiazole ZST152 (49b) was 
 
Scheme 10. Synthetic scheme for generating NG-(2-methoxyethyl)-L-arginine carboxylate bioisosteres.
Reagents and Conditions: (i) CDI, DBU, methanesulfonamide, THF, RT, 7 h, 51%; (ii) HATU,
DIPEA, O-methylhydroxylamine hydrochloride, THF, 0 ˝C-RT, 16 h, 86%; (iii) HATU, DIPEA,
O-benzylhydroxylamine, THF, 0 ˝C-RT, 16 h, 57%; (iv) 4 M HCl/1,4-dioxane, DCM, RT, 30 min, 99%;
(v) DIPEA, DCM, RT, 24 , 43a 42%, 43b 22%, 43c 56%; (vi) TFMSA/TFA, RT, 1 h, 99%. Reproduced in
part from [117] with permission of the Royal Society of Chemistry.
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Other noteworthy inhibitors in this series include the tetrazole 1-[4-amino-4-(1H-tetrazol-5-yl)
butyl]-3-(2-methoxyethyl)guanidine (ZST086, 49a, Scheme 11) and the 5-oxo-1,2,4-oxadiazole
1-[4-amino-4-(5-ox -4,5-dihydro-1,2,4-oxadiazol-3-yl)butyl]-3-(2-methoxyethyl)guanidine (ZST152,
49b, Scheme 11) [117]. The synthesis of these inhibitors w th azole bioisosteric groups is achieved
via conversion of the terminal carboxylic acid in 41 to primary amide 45 in quantitative yields using
isobutylchloroformate, N-m thylmorpholine, and aqueous ammonia. Primary amide 45 is then
converted to nitrile 46 using trifluoroacetic anhydride and triethylamine in 47% yield. Compound
46 is guanylated [112] (see Sections 4.1.3 and 4.1.4 Schemes 7 and 9) to afford compound 47, from
which the heterocycle is constructed from the nitrile. The tetrazole is introduced by treating nitrile
47 with sodium azide in the presence of zinc(II) bromide to afford compound 48a, using the click
chemistry procedure reported by Demko and Sharpless [120]. Although the use of zinc(II) bromide in
the synthesis of Boc-ami o tetrazoles derive from α-amino acid has b en reported [121], the use of
a Lewis acid may result in partial d protection of compound 48a during the reaction. Ammonium
chloride represents an alter ative reagent [122]. The 5-oxo-1,2,4-oxadiazole 48b is synthesized from
nitrile 47 u ing hydroxylamine hydrochloride and sod um bicarbonate in DMSO, followed by tre tment
with CDI and DBU [123]. Acidic deprotection of 48a–b is achieved as described previously [117,119].
Despite obtaining lower yields for heterocyclic adducts 49a–b (7%–13%) relative to bioisosteres 44a–c
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(19%–32%), the inhibitory potential of 5-oxo-1,2,4-oxadiazole ZST152 (49b) was significant (95% at
1 mM, IC50 = 18 µM, Ki = 7 µM), while tetrazole ZST086 (49a) displayed 91% inhibition at 1 mM, with
IC50 = 34 µM and Ki = 14 µM [117].
4.1.6. N5-(1-Iminoalk(en)yl)-L-Ornithine Derivatives
Amidines are commonly known bioisosteres of the guanidine moiety [124]. N5-(1-iminoalk(en)yl)-L-
ornithines such as N5-(1-imino-3-butenyl)-L-ornithine (L-VNIO, 54a, Figure 2), are reported to
inhibit NOS by competing with L-arginine for binding at the enzyme catalytic-site [125–127].
Therefore, derivatives of this class of compounds have been extensively studied as DDAH
inhibitors. The synthetic approach to afford N5-(1-iminoalk(en)yl)-L-ornithine derivatives 54
(Scheme 12) [127,128], utilized a similar approach to the N-but-3-ynyl-2-chloro-acetamidine probe (18)
(see Section 4.1.2, Scheme 5) [109]. The R1 furnished nitrile 50 is converted to its corresponding ethyl
imidic ester 51 by bubbling dry hydrochloric acid gas through a solution of anhydrous ethanol (16).
The ethyl imidic ester 51 is then reacted with Nα-Boc-L-ornithine (52) to afford the protected adduct 53.
Deprotection is obtained by treatment with 6 M HCl to achieve the N5-(1-iminoalk(en)yl)-L-ornithine
54 in excellent overall yields (84%–94%).
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DDAH substrates, ADMA (1) and L-NMMA (2) led different groups to study this class of compounds 
as potential DDAH inhibitors [114,128]. Kotthaus et al. [114] examined five N5-(1-iminoalk(en)yl)-L- 
ornithines with varying side-chain lengths and bond saturation for their ability to inhibit L-citrulline 
formation by human DDAH-1 using both high performance liquid chromatography and colorimetry. 
L-VNIO (54a, Figure 2) emerged as the best DDAH-1 inhibitor of this series of derivatives (97% 
inhibition at 1 mM, IC50 = 13 μM, Ki = 2 μM). However, increasing the main-chain length by one 
carbon atom from ornithine to lysine reduced its DDAH inhibitory potential. 
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Figure 2. N5-(1-Iminoalk(en)yl)-L-ornithine derivatives, L-VNIO (54a), L-IPO (54b), and Cl-NIO (54c),
as synt esized by Kotthaus et al. [114] and Wang et al. [128,129].
The signific nt structural similarity of the N5-(1-iminoalk(en)yl)-L-ornithine derivative with
DDAH substrates, ADMA (1) and L-NMMA (2) led differe t groups to study this class of
compounds as potential DDAH inhibitors [114,128]. Kotthaus et al. [114] examined five
N5-(1-iminoalk(en)yl)-L-ornithines with varying side-chain lengths and bond saturation for their
ability to inhibit L-citrulline formation by human DDAH-1 using both high performance liquid
chromatography and colorimetry. L-VNIO (54a, Figure 2) emerged as the best DDAH-1 inhibitor of
this series of derivatives (97% inhibition at 1 mM, IC50 = 13 µM, Ki = 2 µM). However, increasing the
main-chain length by one carbon atom from ornithine to lysine reduced its DDAH inhibitory potential.
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Wang et al. [128] investigated this class of compounds as dual DDAH-1 and NOS
inhibitors, reporting the synthesis and kinetic parameters for four N5-(1-iminoalkyl)-L-ornithines.
N5-(1-Iminopropyl)-L-ornithine (L-IPO 54b, Figure 2) was identified as the best compound exhibiting
inhibition of both human DDAH-1 (Ki = 52 µM) and rat nNOS (Ki = 3 µM). Wang et al. [129] additionally
developed an irreversible human DDAH-1 inhibitor, N5-(1-imino-2-chloroethyl)-L-ornithine (Cl-NIO,
54c, Figure 2), whose chemical structure reflects a combination of both L-IPO (54b) and
2-chloroacetamidine (11). The synthesis of Cl-NIO (54c) is similar to that described for the
N5-(1-iminoalk(en)yl)-L-ornithine derivatives (Scheme 12). Here, Nα-Boc-L-ornithine is reacted
with 2-chloro-1-ethoxyethanimine, and the intermediate obtained is deprotected with 4.6 M HCl
in dioxane to generate Cl-NIO (54c, Figure 2) in low yields (10%). The inhibition potency of Cl-NIO
(54c) was assessed via colorimetric assay and exhibited Ki = 1.3 µM. In summary, several of the
N5-(1-iminoalk(en)yl)-L-ornithine derivatives (54a–c, Figure 2) are potent human DDAH-1 inhibitors.
Off-target effects on the broader NO pathway (NOSs, arginases, AGTX-2) may either represent an
advantage (strong NO suppression), or limit their application (loss of NO physiological functions) as
potential therapeutics.
4.2. Non-Substrate-Like Inhibitors
4.2.1. Pentafluorophenyl (PFP) Sulfonate Esters
Vallance et al. [130] identified pentafluorophenyl (PFP) sulfonate esters 61 as nonspecific PaDDAH
and bacterial arginine deaminase (ADI) inhibitors, after highlighting their structural similarity with
the cysteine protease family of enzymes. This class of inhibitor can be obtained in moderate to good
yields (44%–75%) via the 1,3-dipolar cycloaddition between nitrone 60 and the electron deficient
vinyl-appended PFP sulfonate 57 (Scheme 13) [131]. The shelf-stable PFP vinylsulfonate 57 is
synthesized in moderate yield (59%) from pentafluorophenol (55) and 2-chloroethane-1-sulfonyl
chloride (56) [132], while various nitrones 60 can be generated from their corresponding aldehydes 58
by reaction with N-methyl hydroxylamine (59) under mild conditions and in good yield (for examples,
please see [133,134]).
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isoxazolidine 61 is increasingly favoured at higher temperatures. Each of the nitrones 60 reported by 
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addition to poly- and hetero-aromatic substituents. This robust synthetic methodology provides the 
ability to generate a structurally diverse library of PFP sulfonate esters 61 with moderate ease and high 
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Scheme 13. Synthetic scheme for generating PFP sulfonate esters 61. Reagents and Conditions: (i) DCM,
TEA, 0 ˝C, 59%; (ii) Method A: NaHCO3, anhydrous MgSO4, DCM, reflux, 24 h, 73%–90% [133];
Method B: NaOAc, EtOH, RT, 90% [134]; (iii) dry toluene, reflux, 1–24 h, 44%–75%. Reproduced in part
from [130–133] with permission of the Royal Society of Chemistry and the American Chemical Society.
The electron deficiency of the vinyl PFP sulfonate dipolarophile 57 affords the reversed
regioselective 4C-substituted adduct of the isoxazolidine in compound 61, contrary to the
5C-substituted adduct typically observed with olefins. Although this was previously observed
for electron deficient dipolarophiles [135–138], Caddick et al. [131] reported the 4C-substituted
isoxazolidine 61 is increasingly favoured at higher temperatures. Each of the nitrones 60 reported by
Caddick et al. [131] participates in cycloaddition with the vinyl PFP sulfonate 57, including C-aryl-
and C-a k l-N-m thyl species with both electron-donating nd electron-withdrawing substituents in
addition to poly- and hetero-aromatic substituents. This robust synthetic methodology provides the
ability to generate a structurally diverse library of PFP sulfonate esters 61 with moderate ease and
high yields [130]. Several PFP sulfonate esters 61 have been screened for their activity as PaDDAH and
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ADI inhibitors at two concentrations (500 µM and 50 µM), with five compounds emerging as relatively
potent PaDDAH inhibitors (IC50 = 16–58 µM, see [130] for structures). Vallance et al. revealed the
mode of inhibition was competitive utilising time-dependence and reversibility experiments [130].
Interestingly, the PFP sulfonate esters 61 have been proposed as potential antibacterial agents, however
no data has been reported identifying if PaDDAH inhibition modulates bacterial growth or viability.
Likewise, no studies utilizing human DDAH have been reported identifying whether the PFP sulfonate
esters exhibit specificity for bacterial PaDDAH. Non-specific PFP sulfonate ester binding to both human
DDAH and PaDDAH would be counterproductive for their proposed application as antibiotics.
4.2.2. Indolylthiobarbituric Acid Derivatives
The indolylthiobarbituric acid derivatives 68 [139] were identified as PaDDAH inhibitors by
a combination of virtual screening using a compound library comprising 308,000 structures and
subsequent biological screening. Among the 109 highest scoring compounds, 90 were commercially
available and used in colorimetric enzyme activity assays. Three compounds consisting of two chemical
scaffolds were identified as potential PaDDAH inhibitors. One of these scaffolds, indolylthiobarbituric
acid (68a), together with additional compounds 68b–c identified from a similarity search, emerged
as promising inhibitors of PaDDAH (IC50 = 2–16.9 µM). The most potent inhibitor of this series was
SR445 (68c, IC50 = 2 µM), and no member of this class of compounds showed any human DDAH
inhibition [114].
This class of inhibitors is comprised of thiobarbituric acid module 64 and indolyl module 67
(Scheme 14). The thiobarbituric acid module 64 is synthesized using a modified version of the method
described by Fisher and Mering in 1903, by reaction of N-substituted 2-thiourea 63 with diethyl
malonate (62) [140,141]. The indolyl module 67 is alkylated by deprotonation of indole-3-carbaldehyde
(65) and reaction with 2-chloro-N-furan-2-ylmethyl-acetimide (66) using a method previously reported
(yield 83%) [142]. The aldehyde substituent of the indolyl derivative 67 is subsequently reacted with
the thiobarbituric acid derivative 64 under acidic conditions to afford 68 (yields not reported) [139,143].
This produced a mixture of (E)- and (Z)-isomers about the linking double bond.
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Scheme 14. Synthetic scheme for generating indolylthiobarbituric acid derivatives 68. Reagents and
Conditions: (i) NaOMe, MeOH, 60 ˝C, 6 h, yields not reported; (ii) NaH, DMF, RT, overnight, 83%;
(iii) 6 M HCl, EtOH, RT, 2–3 h, yields not reported.
4.2.3. Ebselen
Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one, 73), a selenazole heterocyclic compound with
well-known antioxidant properties [144], was recently identified as a potent DDAH-1 inhibitor.
This was achieved by utilizing a high throughput screening (HTS) assay of two commercial libraries
comprising 2446 compounds [145]. The HTS identified each compound’s ability to inhibit the
conversion of the synthetic substrate, S-methyl-L-thiocitrulline (SMTC) to citrulline and methanethiol
by PaDDAH. Compounds exhibiting PaDDAH inhibitory potentials were validated for their ability to
inhibit human DDAH-1 using ADMA as the substrate. The quantification of inhibition was measured
using derivatized citrulline formation and colorimetric detection. Characterisation of PaDDAH and
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human DDAH-1 inhibition by ebselen was subsequently determined by dose-response, reversibility,
and ESI-MS experiments.
While ebselen (73) is commercially available, it can be prepared via two main methods [146–148].
The method described in Scheme 15 [147,148] is preferred due to its shorter reaction times and
elementary design. This method involves the treatment of benzoic acid (69) with thionyl chloride
and aniline to afford benzanilide (70) followed by ortho-lithiation to dianion 71 using n-butyl lithium.
Selenium is then inserted into the carbon-lithium bond of 71, forming dianion intermediate 72, whose
cyclization to ebselen (73) is promoted by copper(II) bromide oxidant.
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Scheme 15. Synthetic scheme for generating ebselen (73). Reagents and Conditions: (i) (1) DCM, pyridine,
SOCl2, reflux, 2 h; (2) toluene, aniline, reflux, 3 h, 80%; (ii) dry THF, n-BuLi, nitrogen atmosphere,
0 ˝C, 30 min, 76% (determined via methylation of 72); (iii) same solution as step (ii), Se, 0 ˝C, 30 min;
(iv) same solution as step (iii), CuBr2, 30 min at ´78 ˝C, then 2 h at RT, 63%. Adapted with permission
from [147], copyright 1989 American Chemical Society, and [148], copyright 2003 The Pharmaceutical
Society of Japan.
Ebselen is reported to irreversibly inhibit both PaDDAH (IC50 = 96 ˘ 2 nM) and human DDAH-1
(IC50 = 330 ˘ 30 nM), forming a covalent selenosulfide bond with each enzyme’s respective catalytic
cysteine. In silico docking experiments suggest inhibitor binding is supported by pi-stacking interactions
with Phe76 in addition to other polar interactions involving His162. In vitro experiments demonstrated
ebselen exhibits no effect on human DDAH-1 expression [145].
Ebselen is the most potent DDAH inhibitor w th ‘non-substrate-like’ structur reported
in the literature to date an demonstrates an anti-inflammatory respo se [149]. However,
its applicati n as a DDAH inhibit r is limited due to its poor DDAH selectivity. A wide range
of molecular targets are modulated by ebselen including: NADPH oxidase 2 [150,151], H+/K+ ATPase
transporter [152], Ca2+- and phospholipid-dependent protein kinase C [151], lipoxygenase [153],
thioredoxin reductase [154], and metallothionein [155]). Moreover, cellular toxicity in leukocytes
and hepatocytes has been reported, further reducing the likelihood of ebselen’s use in clinical
practice [156,157].
4.2.4. 4-Hydroxy-2-Nonenal
4-Hydroxy-2-nonenal (4-HNE, 76) is a cytotoxic aldehyde generated from lipid peroxidation
during inflammati n [158,159] and is abundant in th body. 4-HNE is highly reactive toward
proteinaceous nucl ophilic groups, such as thiol and imidazole moi ties. Nucleophilic attack affords
Michael adducts, whilst Schiff bases are formed with primary amines (e.g., lysine residues) [160–163].
Different methods have been reported for the synthesis of 4-HNE (76) and its derivatives [164–166].
The method reported by Soulér et al. [166] is described here due to its simplicity, speed, and versatility
(Scheme 16). The synthesis is completed in a single cross-metathesis reaction between octen-3-ol (75)
and 2-propenal (74) in the presence of Hoveyda-Grubbs 2nd generation ruthenium catalyst under
a nitrogen atmosphere and in dry oxygen-free solvent (Scheme 16). The reaction proceeds at room
temperature for 25 h affording the (E)-isomer of 4-HNE (76) in 75% yield.
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4-HNE is reported to react with cy teine and histidine residues and it was this r activity that
led Forbes et al. to investigate its use as a human DDAH-1 inhibitor [167]. In Forbes’ experiments,
DDAH activity was measured via both colorimetric and radioisotope activity assays, with 4-HNE
showing dose-dependent inhibition (IC50 = 50 µM) and near complete inhibition at 500 µM. Mass
spectrometry experiments elucidated the mechanism of inhibition, whereby the formation of a Michael
adduct between 4-HNE and His173 of the DDAH-1 active-site occurs.
4.2.5. PD 404182
6H-6-Imino-(2,3,4,5-tetrahydropyrimido)[1,2-c]-[1,3]benzothiazine (PD 404182, 79), is a
commercially available heterocyclic pyri idobenzothiazine and a suitable lead compound for
SAR studies due to its simple synthetic m thodology [168]. PD 404182 (79) is a compound
listed in the Library of Pharma logically Activ Compounds (LOPAC) and is reported to have
antibacterial [168,169] and antiviral [170,171] activity. Ghebremariam et al. [61] utilized a colorimetric
assay to screen a library of over 1200 compounds for their ability to inhibit the conversion of ADMA
to L-citrulline and dimethylamine by recombinant human DDAH-1. Compounds with reasonable
inhibitory potentials were subjected to kinetic characterisation via fluorimetric assay using the synthetic
substrate, S-methylthiocitrulline. Reversibility and ESI-MS studies were additionally undertaken.
PD 404182 was subsequently evaluated for its ability to reduce angiogenesis and to protect against
lipopolysaccharide-induced NO production. PD 404182 (79) was found to be a potent irreversible
comp titive human DDAH-1 inhibitor (IC50 = 9 µM) and showed promise as an anti-inflammatory
and antiangi genic agent.
The synthesis of PD404182 can be achieved via two routes [172,173]. Both approaches
generate reasonable to high yields (61%–88%) over several synthetic steps. The first approach
involves the reaction of 2-(21-haloaryl)-tetrahydropyrimidine 77 with carbon disulfide in the
presence of sodium hydride, followed by hydrolysis of the carbamodithioate derivative 78 and
subsequent treatment with cyanogen bromide to afford 79 (Scheme 17; Route A). Alternatively,
the 2-(21-haloaryl)-tetrahydropyrimidine 77 can be reacted with tert-butylisothiocyanate (80) in the
presence of sodium hydride to afford intermediate 81, followed by treatment with trifluoroacetic acid
to afford 79 (Scheme 17; Route B).
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Sche e 17. Synthetic scheme for generating PD 404182 (79). Reagents and Conditions: Route A: (i) DMF,
NaH, CS2, argon atmosphere, 80 ˝C, 12 h, 88%; (ii) (1) 0.1 M NaOH, MeOH/ 2O (9:1), reflux, 12 h;
(2) anhydrous EtOH, BrCN, argon atmosphere, reflux, 2 h, 61% (two steps). Route B: (iii) DMF, NaH,
argon atmosphere, 80 ˝C, 2 h, 62%; (iv) TFA, CHCl3, molecular sieves 4 Å, reflux, 1 h, 85%. Adapted
with permission from [172,173]. Copyright 1975, 2010 American Chemical Society.
Molecules 2016, 21, 615 16 of 32
4.2.6. Proton Pump Inhibitors
Proton H+/K+ ATPase pump inhibitors (PPIs) are widely prescribed to inhibit gastric acid
secretion and are characterized by a 2-pyridylmethylsulfinylbenzimidazole scaffold. The chemical
structures of the commonly prescribed PPIs 82a–f are shown in Figure 3.
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Further development of the synthetic method to yield omeprazole (82a) [180] identified that the
coupling between the pyridine and benzimidazole moieties can be modified to simplify purification.
Principally, this method avoids the formation of the thioether intermediate 85. Furthermore, the crude
product containing omeprazole (82a) produced from the original synthesis is prone to discolouration
during the oxidation step [180]. The revised synthesis (Scheme 18; Route B) proceeds via condensation
of 2-chloromercaptobenzimidazole derivative 86 with a primary amide pyridine derivative 87 to
afford the acetamide thioether intermediate 88, which is oxidized to the acetamide sulfoxide 89.
Compound 89 is subsequently hydrolysed to the carboxylic acid salt 90 under alkaline conditions, with
decarboxylation yielding omeprazole (82a) or lansoprazole (82c), depending on the benzimidazole 86
and the pyridine 87 derivatives used as the starting materials.
4.2.7. 1,2,3-Triazoles
The synthesis of 1,2,3-triazoles 95 (Scheme 19) comprised of 4-halopyridine and benzimidazole
units have been explored as ‘non-substrate-like’ DDAH-1 inhibitors [117]. The synthesis of these
derivatives was undertaken based on reports that identified binding of both the 4-halopyridine and
benzimidazole fragments to human DDAH-1 [181]. A triazole linker was selected to connect these
fragments via copper(I)-catalysed ‘click’ cycloaddition between the terminal alkyne 92 and azide
94 (Scheme 19). The alkyne 92 is synthesized by Sonogashira coupling of the alkyne derivative
with the required halogenated species 91 [182,183]. The azide 94 is synthesized by reaction of
diphenylphosphoryl azide with the required primary alcohol 93 [184].
Human DDAH-1 inhibition, albeit low (IC50 = 422 µM, 57%, inhibition at 1 mM), was reported
with triazole 95a. In general, 95a–b failed to show significant inhibitory potential and may be due to
the triazole linker not facilitating a productive inhibitory binding conformation of the fragments in the
enzyme active-site.
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5. Conclusions
Current evidence suggest that inhibiting the DDAH family of enzymes may be used as a
therapeutic tool to indirectly inhibit the NOS enzymes via increasing concentrations of endogenous
NOS inhibitors, such as ADMA and L-NMMA. Therefore the development and synthesis of DDAH
inhibitors is emerging as a promising field of clinical research. Furthermore, engineering compounds
that target bacterial DDAH may represent a suitable strategy for the development of new antimicrobial
agents; however further investigations are required. This has led to different classes of DDAH
inhibitors being reported within the last decad characterized by alternative features in terms of
chemical structure, potency, enzyme selectivity, and mechanism of action. The importance placed
on each of these features depen s on the end application of the inhibitor. Table 3 summarizes the
most potent DDAH inhibitors documented in the literature to date. Some compounds, namely PFP
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sulfonate esters 61 or indolylthiobarbituric acid derivatives 68, exhibit significant PaDDAH inhibition.
In particular, selectivity experiments using indolylthiobarbiturates failed to exhibit inhibitory effects
on the human isoenzyme, therefore derivatives of this structural class are well positioned for further
investigation in antibiotic applications. Among classes of molecules which are active on the human
isoenzyme (amino acid derivatives 27, 29, 39, 40, 44, 49, 54, ebselen (73), 4-HNE (76), PD 404182
(79), PPIs 82, 1,2,3-triazoles 95), L-257 (39) and L-291 (40) are highly selective for DDAH-1, while
ornithine derivatives such as L-VNIO (54a) or L-IPO (54b) are known to inhibit not only DDAH, but
also arginase and the NOS family of enzymes. Furthermore, compounds such as ebselen (73) and
4-HNE (76), although very potent DDAH inhibitors, are well known to exhibit a range of off-target
effects, thus are more suitable for experiments in vitro rather than in vivo.
In terms of the varied approaches to chemical synthesis of the DDAH inhibitors discussed here,
many can be synthesized in moderate to excellent overall yields and use reaction sequences that can
be easily modified to enable the design of a large number of analogues. The commercial availability
of several of the compounds determined to be DDAH inhibitors (2-chloroacetamidine (11), ebselen
(73) 4-HNE (76) and the PPIs 82) demonstrates the versatility of some of the synthetic routes for large
scale production.
Based on the in vitro pharmacokinetic and/or enzyme selectivity data compiled in this review,
there appear to be three promising human DDAH-1 inhibitors that have the potential to progress to
clinical trial: ZST316 (Ki = 1 µM), Cl-NIO (Ki = 1.3 µM), and L-257 (Ki = 13 µM) (Table 3). Despite
exhibiting the most potent inhibitory response in vitro, a paucity of data exists with respect to the
in vivo pharmacokinetic and pharmacodynamic profiling of ZST316. Literature reports involving
the enzyme selectivity of Cl-NIO shows considerable promise, with no measurable cross-reactivity
in experiments specifically involving eNOS [129]. However, data are not available regarding this
inhibitor‘s interactions with iNOS, nNOS, or the arginase family of enzymes. Contrary to this, data
reported for L-257 by Kotthaus et al. [115] demonstrates that L-257 is highly selective for DDAH-1.
The administration of L-257 in a rodent model of septic shock not only improved survival, but
additionally improved haemodynamic and organ function [67], indicating a potential clinical role
for L-257.
Interestingly, little is understood about the regulation and pharmacological modulation of
human DDAH-2. As such, the development of improved metabolomic approaches for the sensitive
measurement of DDAH-2 activity in vitro is an important step forward in profiling the endogenous
substrates and biochemical role(s) of this important enzyme in humans.
The continued exploration of DDAH inhibition and the synthesis of new chemical entities with
improved pharmacokinetic parameters are therefore at an exciting junction in the development of
novel medicines.
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Table 3. Summary of the main DDAH inhibitors and their kinetic parameters.
Chemical
Number Chemical Name Chemical Structure Enzyme IC50 (µM) Ki (µM) Kinact (min
´1) Reference
(9) S-Nitroso-L-homocysteine (HcyNO)
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(PD 404182) 
Human DDAH-1 9 - - [61] 
82a–f Proton H
+/K+ ATPase pump 
inhibitors (PPIs) 
Human DDAH-1 51–63 - - [175] 
1 Pa: Pseudomonas aeruginosa; 2 as determined by Tommasi et al. [117]. 
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Abbreviations
The following abbreviations are used in this manuscript:
DDAH Dimethylarginine dimethylamino hydrolase
ADMA Asymmetric dimethylarginine
L-NMMA Monomethyl arginine
NOS Nitric oxide synthase
NO Nitric oxide
SDMA Symmetric dimethylarginine
PRMTs Protein arginine methyl transferases
CAT Cationic amino acid transporter
AGXT2 Alanine-glyoxylate amino transferase 2
PKA Protein kinase A
Akt Protein kinase B
VEGF Vascular endothelial growth factor
iNOS Inducible nitric oxide synthase
TNF-α Tumour necrosis factor α
LDL Low density lipoprotein
IL-1β Interleukin-1β
AT1-R Type 1 angiotensin receptor
DNA Deoxyribonucleic acid
FXR Farnesoid X receptor
HcyNO S-Nitroso-L-homocysteine
NaNO2 Sodium nitrite
NaOH Sodium hydroxide
HCl Hydrochloric acid
Min Minutes
Ki Inhibition constant
µM Micromolar
H2O Water
Cys Cysteine
His Histidine
PaDDAH Pseudomonas aeruginosa dimethylarginine dimethylamino hydrolase
PAD Peptydilarginine deaminase
NaOMe Sodium methoxide
MeOH Methanol
AcOH Acetic acid
NH4Cl Ammonium chloride
PEO Poly(ethylene oxide)
DCM Dichloromethane
TEA Triethylamine
DMAP 4-Dimethylaminopyridine
MsCl Methanesulfonyl chloride
Et2O Diethyl ether
RT Room temperature
NaN3 Sodium azide
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DMF N,N-Dimethylformamide
Ph3P Triphenylphosphine
4124W (S)-2-Amino-4-(3-methylguanidino)butanoic acid
Boc tert-Butyloxycarbonyl
M Molar
DEAD Diethyl azodicarboxylate
THF Tetrahydrofuran
DIPEA N,N-Diisopropylethylamine
CH3CN Acetonitrile
SOCl2 Thionyl chloride
SAR Structure activity relationship
IC50 Inhibition constant
L-257 NG-(2-Methoxyethyl)-L-arginine
L-291 NG-(2-Methoxyethyl)-L-arginine methyl ester
Orn Ornithine
Bu Butyl
Z Carboxybenzyl
TFMSA Trifluoromethanesulfonic acid
TFA Trifluoroacetic acid
CDI 1,11-Carbonyldiimidazole
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
h Hours
HATU
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide
hexafluorophosphate
mM Millimolar
DMSO Dimethyl sulfoxide
i-BuCOCl Isobutyl chloroformate
NH4OH Ammonium hydroxide
TFAA Trifluoroacetic anhydride
ZnBr2 Zinc bromide
NH2OH.HCl Hydroxylamine hydrochloride
NaHCO3 Sodium bicarbonate
L-VNIO N5-(1-Imino-3-butenyl)-L-ornithine
EtOH Ethanol
EtOAc Ethyl acetate
L-IPO N5-(1-Iminopropyl)-L-ornithine
Cl-NIO N5-(1-Imino-2-chloroethyl)-L-ornithine
PFP Pentafluorophenyl
NaOAc Sodium acetate
ADI Arginine deaminase
HTS High throughput screening
SMTC S-methyl-L-thiocitrulline
ESI-MS Electrospray ionization mass spectrometry
BuLi Butyl lithium
Se Selenium
CuBr2 Copper(II) bromide
NADPH Nicotinamide adenine dinucleotide phosphate
H+/K+ ATPase Proton/potassium ATPase
Ca2+ Calcium 2+ cation
4-HNE 4-Hydroxy-2-nonenal
LOPAC Library of Pharmacologically Active Compounds
NaH Sodium hydride
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CS2 Carbon disulfide
BrCN Cyanogen bromide
Å Angstrom
PPIs Proton pump inhibitors
SPR Surface plasmon resonance
CM Carboxymethylated
(Ph3P)2PdCl2 Bis(triphenylphosphine)palladium chloride
CuI Copper(I) iodide
TIPS Triisopropylsilyl
TMS Trimethylsilane
DPPA Diphenylphosphoryl azide
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